由于美元走强，美国制药商辉瑞公司下调了全年的收入和盈利预测。然而，该制药公司公布的第一季度盈利好于预期，得益于其疫苗和抗癌药物的需求。28日上午辉瑞公司的股价在盘前交易大致持平于34.62美元。该公司2014年收入中有60%来自美国以外的国家，其2015年营收预期从445- 465亿美元下调至440-460亿美元

not been well studied. We investigated plasma tau by using an immunomagnetic reduction... set of cognitive function test. We explored their relationships with both brain

;-thalassemia (thal) mutations of the Li people in Hainan Province of China.We have...% carry both α-thal and β-thal mutations. We also examined 9800 subjects

aneurysm.We performed an extensive literature search from 1960 to 2011... factors of aneurysm growth and rupture have been identified. We provide

to emerge that peripheral clocks talk to each other and back to the SCN. As we begin..., so we will begin to elucidate the roles of fine adjusters, such as hormones

critical functions across various biological processes(1,2). Here we use a new... the developmental lineage and differentiation state of the tumours. We observe a

congress, we are not only focused on the imminent problems of epidemics, cares... break through and advances in the field.We have invited numbers of world’

We will feature many opportunities to enhance interactions between students... traditional and core topics. We welcome proposals of special topics that reflect

and vitality.We aresure that you will enjoy your stay in Beijingfrom gaining... with yourcontribution that we can ensure the success of AMS 2014.We lookforward

long way since December 2011 when we met in Adelaide for the Fourth... this website (http://dnabarcodes2013.org or http://dnabarcodes2013.csp.escience.cn) as we

long way since December 2011 when we met in Adelaide for the Fourth...) as we add information (see Important Dates). To receive future notices, online

of gastroenterology.In parallel with our professional endeavors, we will also enjoy... professionals, and industry-sponsored symposia. We look forward to meeting with you

;会议背景介绍： On behalf of the organizing committee, we welcome you

We have to ask a native English speaker for writing assistance.... should be included.R: We think the cause of death should be an acute

Background. Further reduction in the group B streptococcal (GBS) disease burden in neonates in the United States awaits an additional prevention strategy, such as maternal immunization.Methods. We performed a prospective, multicenter, case-control study of 33 mothers delivering neonates with early onset GBS infection (cases), and 99 age- and ethnicity-matched mothers colonized with the same capsular polysaccharide (CPS) types delivering healthy neonates (controls). Relative risk and absolute risk were calculated for early onset disease associated with concentrations of type Ia, III, or V CPS-specific antibody in maternal serum.Results. For GBS types Ia and III, maternal CPS-specific antibody concentrations of ≥0.5 µg/mL were associated with a relative risk of approximately 0.1 (95% confidence intervals [CIs], .01-.74 and 0-.72, respectively; P = .02 for each), corresponding to a 90% risk reduction (by logistic regression). For type V, the relative risk was 0.3 (95% CI, .01-3.1), corresponding to a 70% risk reduction. By Bayesian modeling, the risk of early onset disease would decrease by 70% if maternal CPS-specific antibody concentrations for these 3 GBS types were ≥1 µg/mL.Conclusions. Maternal CPS-specific antibody serum concentrations of ≥1 μg/mL at the time of delivery appear to protect most neonates from early onset GBS type Ia and III disease.

Background. Hepatitis C virus (HCV) is spread through direct contact with blood, although alternative routes of transmission may contribute to the global burden. Perinatal infection occurs in up to 5% of HCV-infected mothers, and presence of HCV RNA in breast milk has been reported. We investigated the influence of breast milk on HCV infectiousness.Methods/Results. Human breast milk reduced HCV infectivity in a dose-dependent manner. This effect was species-specific because milk from various animals did not inhibit HCV infection. Treatment of HCV with human breast milk did not compromise integrity of viral RNA or capsids but destroyed the lipid envelope. Fractionation of breast milk revealed that the antiviral activity is present in the cream fraction containing the fat. Proteolytic digestion of milk proteins had no influence on its antiviral activity, whereas prolonged storage at 4°C increased antiviral activity. Notably, pretreatment with a lipase inhibitor ablated the antiviral activity and specific free fatty acids of breast milk were antiviral.Conclusions. The antiviral activity of breast milk is linked to endogenous lipase-dependent generation of free fatty acids, which destroy the viral lipid envelope. Therefore, nursing by HCV-positive mothers is unlikely to play a major role in vertical transmission.

Background. Targeting host-cell pathways to increase the potency of nucleoside/nucleotide analog reverse transcriptase inhibitors (NRTIs) is an important strategy for clinical investigation. Resveratrol is a natural product that inhibits cellular ribonucleotide reductase, prolonging the S phase of the cell cycle and preferentially lowering dATP levels.Methods. We performed in vitro evaluation of resveratrol on the antiviral activity of adenosine analog tenofovir (TFV) against sensitive and drug-resistant human immunodeficiency virus type 1 (HIV-1), from subtypes B and C, in primary cells.Results. Resveratrol enhanced the antiviral activity of TFV by up to 10-fold and restored susceptibility of TFV-resistant viruses. Resveratrol prevented wild-type HIV-1 from developing phenotypic resistance to TFV. Notably, resveratrol enhanced TFV activity against sensitive and resistant HIV-1 from both subtypes B and C.Conclusions. Prolonged wide-scale use of thymidine analogs in the setting of viral failure has limited the efficacy of second-line NRTI-based regimens in Africa. Moreover, the extensive use of ddI and d4T has led to high frequencies of the K65R mutation, further compromising TFV efficacy. In light of increasing resistance to commonly used NRTIs in global HIV treatment programs, targeting nucleoside biosynthesis with resveratrol, or derivatives with improved bioavailabilities, is a potential strategy to maintain, enhance, and restore susceptibility of commonly used NRTIs.

Background. In treatment-naive, human immunodeficiency virus (HIV)-infected persons, combination antiretroviral therapy (cART) incorporating raltegravir (RAL) is highly effective for virologic suppression, but characteristics of immunologic recovery have not been described.Methods. We performed a 48-week substudy of 15 patients, median age 40 years, within a phase 2 randomized trial of RAL-cART in treatment-naive patients with chronic HIV infection.Results. Plasma viral load decreased from 5.2 ± 5.3 log10 HIV RNA copies/mL to 2.2 ± 2.4 log10 copies/mL at week 4, reaching <50 copies/mL at week 8 in 13 of 15 patients. Total CD4 T cells increased at week 4, as did central memory CD4 T cells in association with reduction of the immune activation markers HLA-DR and CD38 and immune exhaustion marker PD1 in CD4 and CD8 T cells. Naive CD4 T cells increased at week 24 with appearance of HIV gag-specific interleukin 2, interferon-γ, and CD107a responses in CD4 and CD8 T cells at week 48. Plasma lipopolysaccharide and soluble CD14 decreased, but at week 48 were elevated as compared to healthy volunteers. Altogether, the week 48 immune profile was more favorable in patients taking RAL-cART than in patients treated with non-RAL-cART.Conclusions. RAL in first-line treatment regimens results in rapid immune reconstitution with residual low-level microbial translocation.

Background. The incidence and clinical impact of Coronavirus (CoV) infection in elderly persons and those with underlying cardiopulmonary disease over a long duration is not well described. We determined the incidence and clinical impact of 229E and OC43 CoV in this population during four consecutive winters, and compared illnesses to influenza A, respiratory syncytial virus (RSV) and human metapneumovirus (hMPV).Methods. CoV229E and OC43 were detected by RT-PCR and serology in four adult populations under surveillance for acute respiratory illness during the winters of 1999-2003. Cohorts included young healthy adults, healthy elderly, high-risk adults with underlying cardiopulmonary disease, and a hospitalized group.Results. 398 CoV infections were identified, with annual infection rates ranging from 2.8-26% in prospective cohorts, and prevalence ranging from 3.3-11.1% in the hospitalized cohort. The incidence of infections with each strain was similar, although asymptomatic infection and viral co-infection was significantly more common with 229E than OC43 infection. Although the incidence and clinical manifestations were similar for each strain, OC43 infected subjects tended to seek more medical care as OC43 was twice as common as 229E among the hospitalized cohort.Conclusions. CoV infections in the elderly are frequent, likely causing substantial medical disease burden.

Background. Increased pneumococcal loads are associated with severe outcomes. We determined the prevalence of pneumococcal DNA in blood specimens from patients hospitalized with acute lower respiratory tract infection and identified factors associated with invasive pneumococcal pneumonia, bacterial loads, and death.Methods. A total of 8523 patients were enrolled as part of prospective hospital-based surveillance. Blood was collected for quantitative pneumococcal (lytA) detection, and nasopharyngeal specimens were collected for detection of influenza virus and other respiratory viruses by real-time polymerase chain reaction.Results. Of 6396 cases (75%) with lytA results, 422 (7%) were positive for pneumococcal DNA. The prevalences of human immunodeficiency virus (HIV) and influenza virus were 51% (2965/5855) and 8% (485/6358), respectively. On multivariable analysis, HIV infection (adjusted odds ratio [aOR], 2.4; 95% confidence interval [CI], 1.6-3.6), influenza virus coinfection (aOR, 1.4; 95% CI, 1.2-2.1), oxygen therapy during admission (aOR, 1.6; 95% CI, 1.1-2.3) and in-hospital death (aOR, 2.1; 95% CI, 1.1-4.0) were significantly associated with increased pneumococcal load. Among lytA-positive patients, after adjustment for length of hospitalization, duration of symptoms, and oxygen therapy during admission, pneumococcal loads ≥10,000 DNA copies/mL (aOR, 3.6; 95% CI, 1.8-7.2) were associated with increased risk of death.Conclusions. HIV and influenza virus infections were associated with elevated pneumococcal loads, which, in turn, were associated with increased risk of death.